Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. WW
WW logo

WW Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
14.000
Open
13.330
VWAP
13.67
Vol
329.45K
Mkt Cap
137.35M
Low
13.260
Amount
4.50M
EV/EBITDA(TTM)
3.21
Total Shares
10.00M
EV
442.54M
EV/OCF(TTM)
--
P/S(TTM)
0.53
WW International, Inc. provides science-backed weight loss and weight management programs. The Company provides an accessible, holistic model of care through its doctor-recommended Points Program, clinical interventions including weight-loss medications, and community support. Its weight-loss and weight management programs are focused on nutritional and behavior change science. They are comprised of a range of science-based nutritional, activity, behavioral and lifestyle tools and approaches that can be tailored for individual weight goals and, if needed, support the various needs of people taking GLP-1 medications. Its offerings include Behavior Change Programs, WeightWatchers Clinic, Licensing and Consumer Product Sales. Its subscription businesses include digital business, workshops + digital business, clinical business and WeightWatchers for business offering nutritional and behavior change science. Its WW-branded products include bars, snacks, cookbooks and kitchen tools.
Show More

Events Timeline

(ET)
2026-03-31
07:50:00
Novo Nordisk Launches Wegovy Subscription Program, Save Up to $1200 Annually
select
2026-03-16 (ET)
2026-03-16
16:30:00
Stocks Rebound Amid Energy Market Volatility
select
2026-03-16
12:00:00
Stocks Rebound Amid Rising Oil Prices and Geopolitical Tensions
select
2026-03-16
09:00:00
Stock Futures Rise as Markets Seek Recovery
select
2026-03-16
07:10:00
Weight Watchers Q4 Revenue at $163M, Down Year-over-Year
select
2026-03-16
07:10:00
Company Expects 2.65 Million Subscribers in Q1 2026
select
2026-03-11 (ET)
2026-03-11
07:50:00
Playboy Appoints Phillip Picardi as Chief Brand Officer
select
link
2026-02-10 (ET)
2026-02-10
09:10:00
WW International Forms Strategic Partnership with PVOLVE
select

News

Yahoo Finance
7.5
03-16Yahoo Finance
Nasdaq Rebounds as Oil Worries Subside and Tech Gains Drive Market
  • Successful Financing: Century Lithium Corp. completed a C$7 million brokered private placement, issuing 14.89 million units to support its lithium operations in Nevada, which is expected to enhance its market competitiveness and drive future growth.
  • Earnings Beat: WW International shares surged over 12% after reporting stronger-than-expected Q4 and full-year 2025 earnings despite a year-over-year revenue decline, indicating the company's resilience in challenging conditions.
  • Strategic Partnership: Tower Semiconductor's stock rose over 11% following its announcement of a strategic partnership with Oriole Networks to develop photonic networking technologies aimed at improving AI infrastructure, showcasing the company's proactive approach to technological innovation.
  • Government Support: First Phosphate Corp. secured a $16.7 million non-repayable contribution from the Canadian government to advance its Bégin-Lamarche phosphate project in Québec, which is expected to accelerate project progress and enhance the company's standing in the industry.
Yahoo Finance
9.5
03-16Yahoo Finance
WW International Reduces Debt by Over 70% and Repositions Brand
  • Debt Reduction Success: WW International successfully emerged from Chapter 11 financial reorganization, reducing legacy debt by over 70%, which has freed up capital for future investments and enhanced the company's financial flexibility.
  • Clinical Revenue Growth: The company reported a 32% increase in clinical revenue for Q4, driven by the successful launch of its Med+ offering and increased consumer interest in GLP-1 medications, demonstrating the effectiveness of its new strategy.
  • User Growth and Brand Repositioning: 50% of new Med+ members are first-time users, indicating that the brand repositioning strategy has yielded positive results by attracting more new customers and expanding market share.
  • Modernized Technology Infrastructure: WW International launched a new mobile app featuring an AI body scanner and personalized modes, significantly enhancing user experience and further driving member engagement and satisfaction.
seekingalpha
9.5
03-16seekingalpha
WW International Q4 Earnings: Transformation and Growth Insights
  • Debt Reduction and Investment: WW International successfully reduced over 70% of its legacy debt post-bankruptcy, freeing up capital for future investments, with CEO Tara Comonte emphasizing this move as foundational for the company's technology modernization efforts.
  • Clinical Subscriber Growth: As of Q4, clinical subscribers reached 130,000, with expectations to grow to approximately 200,000 by the end of Q1, indicating nearly 100% year-over-year growth and showcasing the company's adaptability in the GLP-1 medication era.
  • Financial Performance and Outlook: Q4 total revenue was $163 million, down 12% year-over-year, yet clinical revenue grew by 32%, with management projecting 2026 revenue between $620 million and $635 million, reflecting confidence in future growth.
  • Market Strategy Shift: The company is transitioning from standalone behavioral offerings to an integrated weight health ecosystem, aiming to recapture lapsed subscribers and drive clinical growth, demonstrating a keen awareness of market changes.
seekingalpha
8.5
03-16seekingalpha
WW International's Transformation Drives Subscriber Growth
  • Significant Subscriber Growth: WW International's transformation to include GLP-1 offerings resulted in a 42% increase in subscribers, indicating initial success in attracting customers and enhancing market competitiveness.
  • Clinical Revenue Boost: Clinical subscription revenue rose by 32% year-over-year by the end of Q4, alleviating the impact of a 12% decline in total revenue and showcasing the potential for future income growth in new business areas.
  • Stock Price Surge: The company's shares opened more than 14% higher on Monday, reflecting positive market sentiment towards its transformation strategy, despite reporting a loss of $0.58 per share, which was better than Wall Street's expectations.
  • Optimistic Future Outlook: WW International anticipates FY26 sales between $620 million and $635 million, slightly below the $633.4 million estimate, but with adjusted EBITDA expectations of $105 million to $115 million, demonstrating confidence in future growth.
seekingalpha
9.5
03-13seekingalpha
WW International, Inc. to Announce Q4 Earnings on March 16
  • Earnings Announcement Schedule: WW International, Inc. is set to release its Q4 2023 earnings report on March 16 before the market opens, with consensus estimates predicting an EPS of -$0.40 and revenue of $149.8 million, indicating challenges in profitability.
  • New Platform Strategy: The company is reinventing itself to capitalize on the GLP-1 drug boom by launching a new platform that integrates behavioral programs, aiming to enhance weight loss outcomes and strengthen its competitive position in the market.
  • Historical Financial Data: Historical financial performance for WW International shows volatility, particularly during its transformation phase, leading investors to closely monitor the upcoming earnings report to assess the effectiveness of the new strategy.
  • Market Reaction Expectations: As the earnings report approaches, market reactions to WW International may be influenced by the integration of its new platform and GLP-1 drugs, with investors eager to see how these strategies will impact the company's future growth potential.
seekingalpha
7.5
03-11seekingalpha
Weight Watchers' GLP-1 Program Shows Significant Weight Loss Benefits
  • Significant Weight Loss: Weight Watchers' GLP-1 Success Program, when combined with weight loss medications, resulted in participants losing up to 61% more weight in the first month and 29% more over a year compared to those using medications alone, highlighting the program's effectiveness.
  • Improved Health Outcomes: CEO Tara Comonte emphasized that while GLP-1 medications are crucial in obesity treatment, they alone cannot ensure lasting results; integrating Weight Watchers' support fosters better health habits and outcomes.
  • Platform Benefits: The Med+ platform offers FDA-approved weight loss medications, access to physicians, and lifestyle support, aimed at helping users establish sustainable habits and mitigate side effects from GLP-1s, thereby enhancing overall weight loss effectiveness.
  • Market Challenges: Despite Weight Watchers' efforts to capitalize on the GLP-1 trend, the stock has declined by 51% since emerging from bankruptcy, indicating significant challenges in the market and the need to validate the long-term effectiveness of its weight loss programs.
Wall Street analysts forecast WW stock price to rise
1 Analyst Rating
Wall Street analysts forecast WW stock price to rise
0 Buy
1 Hold
0 Sell
Hold
Current: 0.000
sliders
Low
38.00
Averages
38.00
High
38.00
Current: 0.000
sliders
Low
38.00
Averages
38.00
High
38.00
Morgan Stanley
Equal Weight
downgrade
$21
AI Analysis
2026-04-01
New
Reason
Morgan Stanley
Price Target
$21
AI Analysis
2026-04-01
New
downgrade
Equal Weight
Reason
Morgan Stanley lowered the firm's price target on WW to $21 from $34.50 and keeps an Equal Weight rating on the shares. A mix shift from behavioral to clinic is happening far faster than the firm anticipated, but this comes with upside as well as "negative trade-offs," the analyst tells investors.
Morgan Stanley
Equal Weight
downgrade
$41 -> $38
2025-11-07
Reason
Morgan Stanley
Price Target
$41 -> $38
2025-11-07
downgrade
Equal Weight
Reason
Morgan Stanley lowered the firm's price target on WW to $38 from $41 and keeps an Equal Weight rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for WW
Unlock Now

Valuation Metrics

The current forward P/E ratio for WW International Inc (WW.O) is 74.07, compared to its 5-year average forward P/E of -9.64. For a more detailed relative valuation and DCF analysis to assess WW International Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-9.64
Current PE
74.07
Overvalued PE
144.21
Undervalued PE
-163.50

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
11.16
Current EV/EBITDA
7.14
Overvalued EV/EBITDA
14.87
Undervalued EV/EBITDA
7.44

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.57
Current PS
0.21
Overvalued PS
1.12
Undervalued PS
0.02

Financials

AI Analysis
Annual
Quarterly

Whales Holding WW

C
Cooper Creek Partners Management LLC
Holding
WW
+13.39%
3M Return
C
Contrarius Investment Management Ltd.
Holding
WW
-2.82%
3M Return
A
Aristeia Capital, LLC
Holding
WW
-6.57%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is WW International Inc (WW) stock price today?

The current price of WW is 13.74 USD — it has increased 4.01

What is WW International Inc (WW)'s business?

WW International, Inc. provides science-backed weight loss and weight management programs. The Company provides an accessible, holistic model of care through its doctor-recommended Points Program, clinical interventions including weight-loss medications, and community support. Its weight-loss and weight management programs are focused on nutritional and behavior change science. They are comprised of a range of science-based nutritional, activity, behavioral and lifestyle tools and approaches that can be tailored for individual weight goals and, if needed, support the various needs of people taking GLP-1 medications. Its offerings include Behavior Change Programs, WeightWatchers Clinic, Licensing and Consumer Product Sales. Its subscription businesses include digital business, workshops + digital business, clinical business and WeightWatchers for business offering nutritional and behavior change science. Its WW-branded products include bars, snacks, cookbooks and kitchen tools.

What is the price predicton of WW Stock?

Wall Street analysts forecast WW stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WW is38.00 USD with a low forecast of 38.00 USD and a high forecast of 38.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is WW International Inc (WW)'s revenue for the last quarter?

WW International Inc revenue for the last quarter amounts to 162.81M USD, decreased -11.71

What is WW International Inc (WW)'s earnings per share (EPS) for the last quarter?

WW International Inc. EPS for the last quarter amounts to -0.58 USD, decreased -287.10

How many employees does WW International Inc (WW). have?

WW International Inc (WW) has 3500 emplpoyees as of April 01 2026.

What is WW International Inc (WW) market cap?

Today WW has the market capitalization of 137.35M USD.